Mark James Litton - 15 Feb 2024 Form 4 Insider Report for Athira Pharma, Inc. (ATHA)

Role
CEO, Director
Signature
/s/ Mark Worthington, Attorney-in-Fact for Mark Litton
Issuer symbol
ATHA
Transactions as of
15 Feb 2024
Net transactions value
$0
Form type
4
Filing time
16 Feb 2024, 17:05:32 UTC
Previous filing
08 Jan 2024
Next filing
05 Sep 2024
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ATHA Stock Option (Right to Buy) Award $0 +650,000 $0.000000 650,000 15 Feb 2024 Common Stock 650,000 $3.66 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Shares subject to the option shall be scheduled to vest monthly over a term of 48 months on the monthly anniversaries of the grant date, subject to the optionee continuing to be a Service Provider (as defined in the Issuer's 2020 Equity Incentive Plan) through the applicable vesting dates.